Showing 111-120 of 655 results for "".
COLLAB CORNER: Long-Term Pediatric Myopia Management
https://modernod.com/podcasts/collaborative-corner-the-podcast/collab-corner-long-term-pediatric-myopia-management/39859/Marc R. Bloomenstein, OD, FAAO, invites Brianna Rhue, OD, FAAO, to review current treatments for pediatric myopia control and share insights into how to talk to patients and their parents about this condition. Dr. Rhue also describes a calculator to help physicians predict myopia in children and sloAn Interview With the Inventor of Rinsada
https://modernod.com/podcasts/to-the-point/an-interview-with-the-inventor-of-rinsada/36934/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, are joined by retina specialist Srinivas Kondapalli, MD, who developed the Rinsada Irrigating Lid Retractor, which effectively cleanses the conjunctival fornix, palpebral conjunctiva, and bulbar conjunctiva.Astigmatism in CL Wearers • Preservative Exposure
https://modernod.com/podcasts/the-mod-pod/astigmatism-in-cl-wearers-preservative-exposure/36853/Jason E. Compton, OD, FAAO, discusses the importance of managing astigmatism in contact lens wearers (0:58). Selina R. McGee, OD, FAAO, talks about the effects of long-term exposure to preservatives when treating chronic ocular conditions (8:37).Considerations for Use of Two Newly Approved Drugs
https://modernod.com/podcasts/to-the-point/considerations-for-use-of-two-newly-approved-drugs/36928/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, discuss factors to consider when bringing perfluorohexyloctane ophthalmic solution (Miebo, Bausch + Lomb) and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals) into your clinical practice.A New Perspective for To the Point
https://modernod.com/podcasts/to-the-point/a-new-perspective-for-to-the-point/36927/This month on To the Point, Jackie Garlich, OD, FAAO, introduces her new co-host, Jessilin Quint, OD, MS, MBA, FAAO. Dr. Quint shares her background and journey in optometry, including how she came to open her dry eye and aesthetics clinic 2 years ago in Maine.An Intro to the Latest Dry Eye Drop
https://modernod.com/podcasts/to-the-point/an-intro-to-the-latest-dry-eye-drop/36925/Get an overview of the recently FDA-approved perfluorohexyloctane ophthalmic solution (Miebo, Bausch + Lomb) from Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO. Drs. O’Dell and Garlich discuss the drop’s mechanism of action, dosing regimen, clinical trial findings, side effect profile, and mStaff Input on Dry Eye Management and Technician Training
https://modernod.com/podcasts/to-the-point/staff-input-on-dry-eye-management-and-technician-training/36916/Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, are joined by Dr. O’Dell’s lead technician, Heather Bollinger. Ms. Bollinger shares questions that have come up while coordinating care for patients with dry eye and imparts her insights on how to effectively train and educate technicians.Treating Soldiers With OSD
https://modernod.com/podcasts/to-the-point/treating-soldiers-with-osd/36915/Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, talk with Elena Carter, OD, who shares her experiences caring for active-duty military and veterans, including how she uses dehydrated amniotic membranes to treat ocular surface disease in these populations.The Makings of a Dry Eye Oasis
https://modernod.com/videos/eye-care-insiders/the-makings-of-a-dry-eye-oasis/37314/In this episode, Joseph J. Allen, OD, FAAO, Dipl ABO, talks with Jessilin Quint, OD, MS, MBA, FAAO, about diagnosing and treating dry eye disease, including what tools and treatments to consider bringing into a practice to get started with this specialty.Case Studies in Treating Ocular Surface Disease: Season 5
https://modernod.com/podcasts/the-mod-pod/case-studies-in-treating-ocular-surface-disease-season-5/36830/The newest season includes a new expert panel featuring Jackie Garlich, OD, FAAO; Justin Schweitzer, OD, FAAO; and William B. Trattler, MD, as they share unique cases of meibomian gland dysfunction, neurotrophic keratitis, and the impact of ocular surface disease on cataract surgery planning.